My clinical research is focused on the design, reporting and regulatory documentations for interventional cardiovascular device trials, including First-in-Human, CE Mark, IDE/IND Phase III and IV trials and post marketing studies in the US and worldwide.
Basic science research had been focused on growth regulatory mechanisms generated by the endothelium-to-cardiomyocytes communication through the endothelium-released nitric oxide, Gi /Gq protein signaling and microRNAs.
Specialized Terms: Ischemic Heart Disease; Medical Devices; Clinical Trial; Endothelium-Cardiomyocytes Communication; Myocardial Hypertrophy; Nitric Oxide; Gi/Gq Signaling; microRNAs.
Dr. Tirziu has made substantial contributions to scientifically sound clinical research documents, regulatory documents (clinical trial protocols and study reports) and meta-analyses to guide clinical investigation on several novel cardiovascular devices and cerebral embolic protection devices during transcatheter heart procedures.
On the basic science front, findings from Dr. Tirziu's laboratory showed that stimulation of angiogenesis in the heart promotes cardiomyocyte growth and myocardial hypertrophy through a nitric oxide (NO)-dependent mechanism involving the degradation of regulator of G protein signaling type 4 (RGS4) and de-repression of the Gβγ/PI3Kγ/Akt/mTORC1 pathway with the up-regulation of miR-182 and miR-146b expression in cardiomyocytes.
Cardiovascular Diseases; Cell Communication; Endothelium, Vascular; Heart Diseases; Heart Failure; Clinical Trial; MicroRNAs; Endothelium-Dependent Relaxing Factors; Gene Regulatory Networks; Publication Characteristics